Thanks to this Professional master’s degree and its 100% online methodology, you will deepen in the design of therapeutic plans in the hospital context involving the most advanced pharmacological products”

Antibiotic resistance is one of the main concerns for healthcare professionals and in particular for those dedicated to Hospital Pharmacy. For this reason, experts dedicated to this area must have a thorough mastery of the principles of pharmacokinetics and pharmacodynamics of these products, allowing them to make more precise recommendations on their use according to the patient's health conditions. In turn, the drugs in this family are continuously evolving to provide more specific therapeutic solutions that reduce their harmful impact on the intestinal flora, among other side effects. Also, specialized pharmacists must manage complementary methods that do not involve this type of products.

Based on all these needs, TECH has designed a Professional master’s degree where students will have the opportunity to update their theoretical and practical knowledge on the most disruptive topics in Hospital Pharmacy. The syllabus delves into different products and updated drug administration techniques for cardiovascular, respiratory or neurological pathologies. On the other hand, the professionals will be able to deal with different intoxications and infectious diseases, as well as their different methods of therapeutic intervention in the context of specific care units or in emergencies. Thus, the syllabus offers all the guarantees for graduates to develop skills focused on efficient and safe pharmacological care in the most complex healthcare environments.

For this academic process, students will use the innovative Relearning methodology. This strategy, exclusive to TECH, facilitates the development of competencies based on the reiteration of complex concepts through different modules of the syllabus. In addition, access to these contents will not be subject to hermetic schedules or continuous evaluations. On the contrary, each participant will have the opportunity to access the materials whenever they prefers. Likewise, the 100% online platform of this program provides a variety of complementary multimedia resources, such as videos and infographics.

Acquire cutting-edge theoretical and practical knowledge through the disruptive and exclusive methodology implemented by TECH: Relearning”

This Professional master’s degree in Hospital Pharmacy contains the most complete and up-to-date scientific program on the market. The most important features include:

• The development of practical cases presented by experts in Pharmacy, Hospital Management, among others
• Graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where self-assessment can be used to improve learning
• Its special emphasis on innovative methodologies
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

This program will delve into the toxicokinetics and toxic effects of some drugs to prevent the occurrence of secondary discomfort or potential allergies in hospitalized patients”

The program’s teaching staff includes professionals from sector who contribute their work experience to this educational program, as well as renowned specialists from leading societies and prestigious universities.

Its multimedia content, developed with the latest educational technology, will provide the professionals with situated and contextual learning, i.e., a simulated environment that will provide an immersive education programmed to learn in real situations.

The design of this program focuses on Problem-Based Learning, by means of which the professionals must try to solve the different professional practice situations that are presented throughout the academic course. For this purpose, the students will be assisted by an innovative interactive video system created by renowned experts.

A university qualification that you can access from the mobile device of your choice, anytime, anywhere, or by downloading its materials to consult them offline"

With this very complete TECH syllabus you will specialize as a hospital pharmacist in the pharmacological options for the management of Acute Pain in people with polytrauma"

Hospital Pharmacy must offer services to a wide range of healthcare units, including emergency care, infectious diseases, neurological pathologies, among others. In this university program, professionals will be able to get up to date on the most advanced drugs and their forms of administration in the internal context of healthcare facilities. The syllabus, designed by the best experts, covers innovative aspects such as immunomodulatory therapies for conditions such as Myasthenia Gravis. In short, each module addresses specific aspects and provides practical skills using disruptive methods such as Relearning.

The innovative and unique methodologies of this program will enable you to master complex concepts related to Hospital Pharmacy in an efficient, fast and flexible way”

Module 1. Pharmacology of the Cardiovascular System

1.1. Acute Coronary Syndrome (ACS)

1.1.1. ST NSTEACS Segment-Elevation ACS
1.1.2. Non NSTEACS ST-Segment-Elevation in ACS
1.1.3. Unstable Angina

1.2. Heart Failure

1.2.1. Acute exacerbation of HF
1.2.2. Moderate acute HF with water overload
1.2.3. Acute hypertensive HF: acute pulmonary edema (PEA)
1.2.4. Acute hypotensive HF: Cardiogenic Shock
1.2.5. HF with increased systolic volume
1.2.6. Acute HF and atrial fibrillation
1.2.7. Acute HF and renal injury
1.2.8. Hyperkalemia in acute HF
1.2.9. HF of any type

1.3. Cardiac Arrhythmias

1.3.1. Initial management of the patient with tachycardia
1.3.2. Unstable tachycardia with a pulse
1.3.3. Stable tachycardia
1.3.4. Cardio-respiratory arrest (CRA)

1.4. Antihypertensives

1.4.1. Angiotensin-converting enzyme inhibitors (ACEI)
1.4.2. Angiotensin receptor blockers (ARBs)
1.4.3. Diuretics
1.4.4. Beta-blockers

1.5. Antiarrhythmics

1.5.1. Class I
1.5.2. Class II
1.5.3. Class III
1.5.4. Class IV

1.6. Drugs for the treatment of coronary heart disease

1.6.1. Platelet Aggregation Inhibitors
1.6.2. Beta-Blockers
1.6.3. Nitrates
1.6.4. Angiotensin-converting enzyme inhibitors (ACEI)

1.7. Anticoagulants

1.7.1. Oral anticoagulants
1.7.2. Vitamin K Antagonists
1.7.3. Direct thrombin inhibitors
1.7.4. Parenteral anticoagulants

1.8. Drugs in the treatment of deep vein thrombosis and pulmonary embolism

1.8.1. Pathophysiology of deep vein thrombosis
1.8.2. Pharmacology of anticoagulants used in the treatment of DVT and PE
1.8.3. Thrombolytic drugs
1.8.4. Anticoagulant therapy in the acute and chronic management of DVT and PE

1.9. Drugs in the Treatment of Angina Pectoris

1.9.1. Pathophysiology of angina pectoris
1.9.2. Fundamentals on Cardiovascular Pharmacology
1.9.3. Classification of drugs for the treatment of Angina Pectoris
1.9.4. Use of beta-blockers in the management of Angina Pectoris: Indications and Mechanisms of Action

1.10. Drugs in the Treatment of Pulmonary Hypertension

1.10.1. Pathophysiology of Pulmonary Hypertension
1.10.2. Fundamentals on Cardiovascular Pharmacology
1.10.3. Pharmacology of PDE5 inhibitors in the treatment of Pulmonary Hypertension
1.10.4. Pharmacology of soluble guanylate cyclase stimulators in the treatment of pulmonary hypertension

Module 2. Pharmacology of the Respiratory System

2.1. Asthmatic exacerbation

2.1.1. Underlying mechanisms
2.1.2. Emerging therapies
2.1.3. Risk Factors
2.1.4. Prevention strategies

2.2. Acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

2.2.1. Antibiotics
2.2.2. Medical treatment
2.2.3. Oxygen Therapy
2.2.4. Prevention strategies

2.3. Allergic Reaction

2.3.1. Classification of allergies
2.3.2. Types of allergy
2.3.3. Diagnosis
2.3.4. Immunotherapy

2.4. Anaphylaxis

2.4.1. Clinical diagnosis
2.4.2. Emergency Treatment
2.4.3. Idiopathic Anaphylaxis
2.4.4. Anaphylaxis in pediatrics

2.5. Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

2.5.1. Risk factors and triggers for SJS and TEN
2.5.2. Clinical and differential diagnosis of JSS and TEN
2.5.3. Emergency management and treatment of JSS and NETs
2.5.4. Role of drugs and infectious agents in the development of JSS and NET

2.6. Rapid Induction and Intubation Sequence (SIIR)

2.6.1. Indications and contraindications for SIIR
2.6.2. Complications and risks associated with SIIR and its management
2.6.3. Techniques and approaches for rapid and safe intubation in emergency situations
2.6.4. Monitoring and evaluation during SIIR

2.7. Post-intubation sedoanalgesia

2.7.1. Pharmacology of sedative and analgesic agents
2.7.2. Assessment and monitoring of the level of sedation
2.7.3. Strategies for pain control in postintubation patients
2.7.4. Differences in sedation and analgesia according to the type of unit

2.8. Pharmacology of Bronchodilators

2.8.1. Action Mechanisms of Bronchodilators
2.8.2. Classification of bronchodilators according to their duration of action and potency
2.8.3. Short-acting versus long-acting bronchodilators
2.8.4. Adverse effects and safety of bronchodilators

2.9. Pharmacology of Mucolytics and Expectorants in Respiratory Diseases

2.9.1. Principles of absorption, distribution, metabolism and excretion of respiratory drugs
2.9.2. Influence of age, gender and pathological conditions
2.9.3. Evaluation of the bioavailability of respiratory drugs
2.9.4. Optimization of respiratory drug formulations for better absorption and bioavailability

2.10. Pharmacology of antibiotics and antivirals in respiratory infections

2.10.1. Classification of antibiotics and antivirals used in respiratory infections
2.10.2. Mechanisms of Action of Antibiotic and Antivirals
2.10.3. Resistance to Antibiotics and Antiviral
2.10.4. Rational Use of Antibiotics and Antiviral

Module 3. Pharmacology of Epilepsy, Migraine and Myasthenia Gravis

3.1. Adult Patient Seizures

3.1.1. Classification of Seizures
3.1.2. Differential diagnosis and clinical evaluation
3.1.3. Neuroimaging Studies in Diagnosis
3.1.4. Pharmacological treatment of seizures in the adult patient

3.2. Seizures in the pediatric patient

3.2.1. Classification of seizures in the pediatric patient
3.2.2. Differential diagnosis and clinical evaluation of seizures in the pediatric patient
3.2.3. Neuroimaging studies in the diagnosis of seizures in the pediatric patient
3.2.4. Febrile seizures in childhood

3.3. Status Epilepticus (SE) in the adult patient

3.3.1. Diagnosis and clinical evaluation of Status Epilepticus
3.3.2. Neurophysiological evaluation and neuroimaging in Status Epilepticus
3.3.3. Causes and triggers of Status Epilepticus in adults
3.3.4. Emergency management and treatment of Status Epilepticus in the adult patient

3.4. SE in the pediatric patient

3.4.1. Diagnosis and clinical evaluation of Status Epilepticus in the pediatric patient
3.4.2. Neurophysiological assessment and neuroimaging in pediatric Status Epilepticus
3.4.3. Causes and triggers of Status Epilepticus in children
3.4.4. Emergency management and treatment of Status Epilepticus in the pediatric patient

3.5. Management of Myasthenia Gravis (MG)

3.5.1. Classification of Myasthenia Gravis
3.5.2. Pharmacological Treatment of Myasthenia Gravis
3.5.3. Management of myasthenic crisis and acute exacerbations of myasthenia gravis
3.5.4. Immunomodulatory and biological therapies in myasthenia gravis

3.6. Headache and Migraine in the adult patient

3.6.1. Classification of primary and secondary headaches
3.6.2. Clinical evaluation and differential diagnosis of headache and Migraine in the adult patient
3.6.3. Initial therapeutic approach and management of episodic migraine
3.6.4. Migraine prophylaxis and prevention of chronic migraine headaches

3.7. Headache and Migraine in the pediatric patient

3.7.1. Classification of primary and secondary headaches in children
3.7.2. Clinical evaluation and differential diagnosis of headache and Migraine in the pediatric patient
3.7.3. Differences in the presentation and manifestation of Migraine in children and adults
3.7.4. Acute pharmacological treatment of migraine attacks in children

3.8. Hypertensive Emergencies

3.8.1. Classification and categories of hypertensive emergency
3.8.2. Clinical Evaluation and Diagnosis of Hypertensive Emergencies
3.8.3. Complementary tests and laboratory studies for the evaluation of hypertensive emergency
3.8.4. Differentiation between hypertensive emergency and hypertensive urgency

3.9. Pathophysiology of Epilepsy

3.9.1. Pharmacokinetics of antiepileptic drugs
3.9.2. Pharmacological interactions of antiepileptic drugs
3.9.3. Combination treatment strategies
3.9.4. Use of antiepileptic drugs in special populations

3.10. Emerging and developing therapies for Migraine treatment

3.10.1. Therapies specifically targeting the pathophysiology of Migraine
3.10.2. Monoclonal therapies directed against calcitonin gene-related peptide (CGRP) in Migraine
3.10.3. PDE4 inhibitors as an emerging treatment for Migraine
3.10.4. Use of monoclonal antibodies in the prophylactic treatment of Migraine

Module 4. Pharmacology of the Central Nervous System

4.1. Ischemic Strokes

4.1.1. Advances in the early diagnosis of ischemic stroke
4.1.2. Evaluation and classification of the risk of ischemic stroke in asymptomatic patients
4.1.3. Thrombolytic treatment strategies in the acute phase of ischemic stroke
4.1.4. Biomarkers in Ischemic Stroke

4.2. Management of hypertension in acute ischemic stroke

4.2.1. Current guidelines and protocols for the management of hypertension in acute ischemic stroke
4.2.2. Pharmacologic treatment of hypertension in the acute phase of ischemic stroke
4.2.3. Blood pressure control strategies in ischemic stroke with thrombolytic therapy
4.2.4. Endovascular therapy and blood pressure control in acute ischemic stroke

4.3. Oropharyngeal angioedema due to Alteplase

4.3.1. Risk factors for the development of oropharyngeal angioedema after Alteplase administration
4.3.2. Clinical and differential diagnosis of oropharyngeal angioedema in patients treated with Aateplase
4.3.3. Management and treatment of acute oropharyngeal angioedema by Alteplase
4.3.4. Evaluation and follow-up of patients with a history of oropharyngeal angioedema prior to administration of Alteplase

4.4. Hemorrhagic stroke: intracerebral hemorrhage (ICH)

4.4.1. Diagnosis and classification of intracerebral hemorrhage in hemorrhagic stroke
4.4.2. Medical and pharmacological treatment of acute intracerebral hemorrhage
4.4.3. Neurosurgical and endovascular management of intracerebral hemorrhage
4.4.4. Multidisciplinary approach in the care of the patient with intracerebral hemorrhage

4.5. Cerebral edema

4.5.1. Cytotoxic versus vasogenic cerebral edema
4.5.2. Clinical evaluation and imaging of cerebral edema
4.5.3. Pharmacological strategies for the reduction of cerebral edema in specific pathologies
4.5.4. Effect of cerebral edema

4.6. Opioid overdose

4.6.1. Pharmacokinetics and pharmacodynamics of opioids involved in overdose
4.6.2. Role of the hospital pharmacist in opioid overdose prevention and education
4.6.3. Management of opioid withdrawal in the hospital setting
4.6.4. Naloxone and its use as an antidote in opioid overdose reversal

4.7. Opioid Withdrawal Syndrome

4.7.1. Epidemiology and risk factors for the development of Opioid Withdrawal Syndrome
4.7.2. Clinical evaluation and diagnosis of Opioid Withdrawal Syndrome in hospitalized patients
4.7.3. Pharmacological management of Opioid Withdrawal Syndrome in the hospital setting
4.7.4. Use of opioid agonist and antagonist drugs in the treatment of withdrawal syndrome

4.8. Agitated Patient Management

4.8.1. Epidemiology and risk factors associated with agitation in hospitalized patients
4.8.2. Pharmacotherapy for the management of acute agitation in inpatients
4.8.3. Use of antipsychotics and benzodiazepines in the treatment of agitation
4.8.4. Safety and prevention of complications in the management of the agitated patient

4.9. Acute pain management in the patient with substance abuse

4.9.1. Pharmacological interactions between analgesics and substances of abuse
4.9.2. Pharmacological strategies for acute pain management in patients with opioid abuse
4.9.3. Acute pain Treatment in patient with Alcohol abuse
4.9.4. Assessment and management of addiction risk in patients with substance abuse requiring analgesia

4.10. Alcohol Withdrawal Syndrome

4.10.1. Clinical evaluation and diagnosis of Alcohol Withdrawal Syndrome in hospitalized patients
4.10.2. Pharmacotherapy for the management of Alcohol Withdrawal Syndrome in the inpatient setting
4.10.3. Use of benzodiazepines and other drugs in the treatment of Alcohol Withdrawal Syndrome
4.10.4. Role of the hospital pharmacist in the management of Alcohol Withdrawal Syndrome

Module 5. Pharmacology of the Gastrointestinal System

5.1. Chronic Hepatic Disease

5.1.1. Diagnosis and classification of chronic liver diseases
5.1.2. Biomarkers and liver function tests in diagnosis and follow-up
5.1.3. Strategies for management and prevention of disease progression
5.1.4. Pharmacological treatment of chronic liver disease

5.2. Upper gastrointestinal bleeding (UGH)

5.2.1. Epidemiology and risk factors associated to Upper Gastrointestinal Bleeding
5.2.2. Classification and Etiology of Upper Gastrointestinal Bleeding
5.2.3. Diagnosis and early detection methods of HDA
5.2.4. Pharmacological Treatment of HDA

5.3. Spontaneous Bacterial Peritonitis (SBP)

5.3.1. Anatomy and physiology of the peritoneum and its relationship with PBE
5.3.2. Clinical diagnosis and methods of detection of spontaneous bacterial peritonitis
5.3.3. Evaluation and classification of patients with SBP
5.3.4. Pharmacological treatment of spontaneous bacterial peritonitis

5.4. Hydroelectrolytic Alterations

5.4.1. Sodium
5.4.2. Chlorine
5.4.3. Potassium
5.4.4. Phosphorus

5.5. Clostridium difficile infection (CDI)

5.5.1. Epidemiology and risk factors associated to CDI
5.5.2. CDI Diagnosis
5.5.3. Clinical evaluation of the patient with Clostridium difficile infection
5.5.4. Pharmacological Treatment of CDI

5.6. Complicated intra-abdominal infection (CAIbc)

5.6.1. Epidemiology and risk factors associated to complicated intra-abdominal infection
5.6.2. Etiology and pathogenesis of cCBI
5.6.3. Clinical evaluation of the patient with cBAI
5.6.4. Pharmacological treatment of complicated intra-abdominal infection

5.7. Pancreatitis

5.7.1. Epidemiology and risk factors associated to Pancreatitis
5.7.2. Etiology and Classification of Pancreatitis
5.7.3. Clinical diagnosis and methods of detection of Pancreatitis
5.7.4. Pharmacological treatment of acute and chronic pancreatitis

5.8. Irritable Bowel Syndrome

5.8.1. Anatomy and physiology of the gastrointestinal system related to irritable bowel syndrome
5.8.2. Etiology and pathogenesis of irritable bowel syndrome
5.8.3. Classification and subtypes of IBS
5.8.4. Medical treatment of irritable bowel syndrome

5.9. Prokinetics and antiemetics

5.9.1. Anatomy and physiology of the gastrointestinal system and the control of motility
5.9.2. Classification and mechanisms of action of prokinetics and antiemetics
5.9.3. Indications and contraindications for the use of prokinetics and antiemetics
5.9.4. Pharmacological treatment of nausea and vomiting induced by opioids and other drugs

5.10. Pharmacology of drugs used in nutritional therapy

5.10.1. Classification and Types of nutritional therapy
5.10.2. Administration of drugs and enteral nutrition: interactions and special considerations
5.10.3. Medications used for the management of malnutrition and nutritional support in critically ill patients
5.10.4. Antibiotics and antifungals in enteral and parenteral nutrition patients

Module 6. Pharmacology of infectious diseases and intoxications

6.1. Responsible Antibiotic Use

6.1.1. Classification
6.1.2. Mechanisms of action
6.1.3. Spectrum of activity
6.1.4. Principles of antibiotic pharmacokinetics and pharmacodynamics

6.2. Urinary Tract Infections(ITU)

6.2.1. Anatomy and physiology of the urinary tract related to urinary tract infection
6.2.2. Etiology and pathogenesis of cCBI
6.2.3. Classification of Urinary Tract Infection
6.2.4. Pharmacologic treatment of urinary tract infection

6.3. Skin and soft tissue infection (STEMI)

6.3.1. Anatomy and physiology of skin and soft tissues related to IPPB
6.3.2. Classification and Types of Skin and Soft Tissue Infections
6.3.3. Evaluation of the patient with IPPB in the hospital setting
6.3.4. Pharmacologic treatment of Skin and Soft Tissue Infections

6.4. Pneumonia

6.4.1. Anatomy and physiology of the Respiratory System relationship with Pneumonia
6.4.2. Etiology and pathogenesis of pneumonia
6.4.3. Classification of pneumonia according to etiology and severity
6.4.4. Pharmacological Treatment of Pneumonia

6.5. Meningitis

6.5.1. Anatomy and physiology of the central nervous system relationship with Meningitis
6.5.2. Classification of meningitis according to the causative agent and the clinical presentation
6.5.3. Evaluation and classification of the patient with meningitis
6.5.4. Pharmacological Treatment of Meningitis

6.6. Sepsis

6.6.1. Anatomy and physiology of the immune system related to sepsis
6.6.2. Etiology and pathogenesis of Sepsis
6.6.3. Classification and Stages of Sepsis
6.6.4. Pharmacological Treatment of Sepsis

6.7. Acute psychosis and delirium

6.7.1. Etiology and pathogenesis of acute psychosis and delirium
6.7.2. Classification and subtypes of acute psychosis delirium
6.7.3. Assessment and classification of the patient with acute psychosis and delirium in the hospital setting
6.7.4. Pharmacological treatment of acute psychosis and delirium

6.8. Acetylsalicylic acid (ASA) intoxication

6.8.1. Toxicokinetics of acetylsalicylic acid in intoxication
6.8.2. Toxic effects and clinical symptoms associated with acetylsalicylic acid poisoning
6.8.3. Clinical diagnosis and methods of detection of AAS poisoning
6.8.4. Treatment and pharmacotherapeutic management of ASA poisoning

6.9. Paracetamol poisoning

6.9.1. Toxicokinetics of Paracetamol in poisoning
6.9.2. Toxic effects and clinical symptoms associated with Paracetamol poisoning
6.9.3. Clinical diagnosis and methods of detection of Paracetamol poisoning
6.9.4. Treatment and pharmacotherapeutic management of ASA poisoning

6.10. Antidotes

6.10.1. General principles of poisoning management in the hospital setting
6.10.2. Identification and diagnosis of poisonings and intoxications
6.10.3. Pharmacotherapeutic management of poisonings
6.10.4. Use and administration of antidotes in specific poisonings

Module 7. Hospital Pharmacology Management

7.1. Human Resources Management in the Hospital Pharmacy Department

7.1.1. Organization of the Hospital Pharmacy Department
7.1.2. Roles of the pharmaceutical staff
7.1.3. Performance evaluation and professional development of the pharmaceutical staff
7.1.4. Design of education and training programs for pharmaceutical personnel

7.2. Information technologies applied to Hospital Pharmacy management

7.2.1. Hospital information systems and their integration with the Pharmacy department
7.2.2. Electronic medical records and pharmacotherapeutic registries in the hospital environment
7.2.3. Automation and robotics in the preparation and dispensing of medications
7.2.4. Inventory management and stock control systems in the pharmacy department

7.3. Inventory management and pharmaceutical logistics in hospitals

7.3.1. Organization and structure of the pharmacy department in the context of hospital logistics
7.3.2. Selection and evaluation of pharmaceutical suppliers
7.3.3. Receipt, storage and distribution of drugs and pharmaceuticals
7.3.4. Rotation and expiration of inventory in the hospital environment

7.4. Pharmacoeconomics and health technology assessment

7.4.1. Methods and techniques of health economic analysis
7.4.2. Analysis of efficiency and equity in the use of resources in the health sector
7.4.3. Assessment of health outcomes and health-related quality of life
7.4.4. Use of health and economic indicators in clinical and administrative decision making

7.5. Development and monitoring of protocols for the use of drugs in hospitals

7.5.1. The role of the hospital pharmacist in the development of protocols
7.5.2. Design and development of protocols for the safe and efficient use of medications
7.5.3. Implementation and dissemination of protocols in the health care team
7.5.4. Integration of medication use protocols with the hospital information system

7.6. Pharmacovigilance and patient safety in the administration of medications

7.6.1. Pharmacovigilance systems and databases in the hospital setting
7.6.2. Reporting and recording of adverse drug-related events
7.6.3. Methods for the early detection of adverse drug reactions
7.6.4. Active and passive pharmacovigilance in hospital pharmacy

7.7. Ambulatory clinical pharmacy and outpatient care

7.7.1. Models of outpatient pharmaceutical care in the hospital setting
7.7.2. Pharmaceutical evaluation of outpatients: collection and analysis of clinical and pharmacotherapeutic data
7.7.3. Elaboration of pharmacological treatment plans and outpatient monitoring
7.7.4. Use of information technologies in outpatient pharmaceutical care

7.8. Quality Management and Continuous Improvement in Hospital Pharmacy

7.8.1. quality standards applicable to hospital pharmacy
7.8.2. Implement of quality management system
7.8.3. Evaluation and improvement of processes in the hospital pharmacy area
7.8.4. Internal and external audits in hospital pharmacy quality management

7.9. Integration of hospital pharmacy in multidisciplinary health teams

7.9.1. Models of interprofessional and multidisciplinary care in the hospital setting
7.9.2. Roles and responsibilities of the pharmacist in multidisciplinary health teams
7.9.3. Effective communication and collaboration among health care professionals in the hospital setting
7.9.4. Clinical cases and case discussion in multidisciplinary teams

7.10. Project Management and Strategic Planning in Hospital Pharmacy

7.10.1. Processes and methodologies for project management in the field of hospital pharmacy
7.10.2. Identification and formulation of pharmaceutical projects in hospital pharmacy
7.10.3. Planning and organization of resources for the implementation of projects
7.10.4. Implementation and follow-up of pharmaceutical projects

Module 8. Pharmacology of the surgical and polytraumatized patient

8.1. Triage

8.1.1. Triage in emergency and disaster situations:
8.1.2. Triage systems used in the hospital setting and their characteristics
8.1.3. Role of the pharmacist in the triage process and emergency care
8.1.4. Pharmaceutical triage protocols in different clinical scenarios

8.2. Resuscitation in the polytraumatized patient (PPT)

8.2.1. Hospital pharmacy in the PPT resuscitation team
8.2.2. Pharmacology of resuscitation: drugs and therapies used in PPT
8.2.3. Fluid therapy in the polytraumatized patient: types of solutions and considerations
8.2.4. Analgesia and sedation in the polytraumatized patient

8.3. Cranioencephalic Trauma (CET)

8.3.1. Classification and Severity of CET
8.3.2. Pain management and sedation in patients with CET
8.3.3. Treatment of Intracranial Hypertension
8.3.4. Use of neuroprotective agents in CET

8.4. Reversal of anticoagulants

8.4.1. Importance of anticoagulant reversal in specific clinical situations
8.4.2. Risk-benefit assessment in anticoagulant reversal
8.4.3. Reversal of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH)
8.4.4. Antidotes and reversal agents for direct oral anticoagulants (OACDs)

8.5. Acute Pain Management

8.5.1. Classification and scales for the evaluation of acute pain
8.5.2. Principles and guidelines of pharmacological management of acute pain
8.5.3. Multimodal Analgesia
8.5.4. Intravenous, oral and transdermal analgesia

8.6. Spinal Shock

8.6.1. Evaluation and classification of spinal shock
8.6.2. Medications to stabilize blood pressure in spinal cord shock
8.6.3. Pain Management in Patients with Spinal shock
8.6.4. Neuroprotective agents in spinal shock

8.7. Hypovolemic Shock

8.7.1. Evaluation and classification of Hypovolemic Shock
8.7.2. Fluid therapy and volume replacement in hypovolemic shock
8.7.3. Types of solutions and electrolytes used in volume replacement
8.7.4. Use of vasoactive agents in the management of hypovolemic shock

8.8. Penetrating Trauma

8.8.1. Evaluation and classification of patients with penetrating trauma
8.8.2. Initial management and pharmacological stabilization of the trauma patient
8.8.3. Use of hemostatic agents and pharmacologic hemostasis
8.8.4. Antibiotherapy in penetrating trauma patients

8.9. Open Fractures

8.9.1. Initial evaluation and emergency management of patients with open fractures
8.9.2. Use of analgesia and sedation in patients with open fractures
8.9.3. Adjuvant therapies in the acceleration of bone healing
8.9.4. Use of analgesics and anti-inflammatory drugs in the management of pain in open fractures

8.10. Moderate sedation

8.10.1. Indications and contraindications of moderate sedation
8.10.2. Evaluation and selection of the appropriate level of sedation for each patient
8.10.3. Management of anxiety and pain in procedures with moderate sedation
8.10.4. Monitoring and patient safety during moderate sedation

Module 9. Pharmacology of the Genitourinary, Obstetric and Gynecologic System

9.1. Sexual Assault

9.1.1. Medical and pharmacological considerations in the immediate care of victims of sexual assault
9.1.2. Pharmacotherapy for the prevention and treatment of sexually transmitted infections (STIs)
9.1.3. Post-exposure prophylaxis (PEP) for HIV and other STIs in victims of sexual assault
9.1.4. Pharmacologic therapy to prevent and treat physical injuries and psychological complications

9.2. Sexually Transmitted Diseases

9.2.1. Epidemiology of sexually transmitted diseases
9.2.2. Prevention and promotion of sexual health in at-risk populations
9.2.3. Pharmacotherapy for the treatment of sexually transmitted infections (STIs)
9.2.4. Post-exposure prophylaxis (PEP) for HIV and other STIs

9.3. Gestational hypertension

9.3.1. Classification and diagnosis of gestational hypertension
9.3.2. Pharmacology of drugs used in the management of gestational hypertension
9.3.3. Monitoring and control of blood pressure in pregnant women
9.3.4. Pharmacological management of mild and severe gestational hypertension

9.4. Venous thromboembolism

9.4.1. Classification and diagnosis of venous thromboembolism
9.4.2. Pharmacology of anticoagulants used in the treatment of VTE
9.4.3. Use of parenteral and oral anticoagulants in the management of VTE
9.4.4. VTE prophylaxis in hospitalized and surgical patients

9.5. Acute uncomplicated cystitis

9.5.1. Classification and diagnosis of Acute Cystitis
9.5.2. Pharmacology of antibiotics used in the treatment of Acute Cystitis
9.5.3. Use of analgesic drugs in pain relief in acute cystitis
9.5.4. Alternatives to antibiotics in the treatment of Acute Cystitis

9.6. Urinary Tract Infections

9.6.1. Classification and diagnosis of Urinary Tract Infection
9.6.2. Pharmacology of antibiotics used in the treatment of the ITU
9.6.3. Use of analgesic drugs in pain relief in the ITU
9.6.4. Treatment of complicated and recurrent urinary tract infections

9.7. Pathophysiology of the Genitourinary System

9.7.1. Principles of absorption
9.7.2. Principles of metabolism
9.7.3. Principles of excretion
9.7.4. Relevant drug interactions in the area of Gynecology

9.8. Pharmacology of drugs used in the Genitourinary System

9.8.1. Drugs used in the treatment of urinary tract infections (UTI)
9.8.2. Drugs used in the treatment of erectile dysfunction and other sexual disorders
9.8.3. Pharmacotherapy in the management of benign prostatic hyperplasia (BPH)
9.8.4. Medications for the management of renal disorders, such as nephritis and chronic renal failure

9.9. Pathophysiology and Pharmacology of the Obstetrical System

9.9.1. Pharmacology of prenatal supplements and micronutrients used in pregnancy
9.9.2. Drugs used in the treatment of nausea and vomiting of pregnancy
9.9.3. Drugs for the management of hypertensive disorders in pregnancy (preeclampsia and eclampsia)
9.9.4. Use of drugs in the prevention and treatment of infections during pregnancy

9.10. Pathophysiology of menstrual disorders

9.10.1. Menstrual bleeding disorders: menorrhagia, metrorrhagia, and hypomenorrhea
9.10.2. Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD)
9.10.3. Endometriosis: pathologic mechanisms and clinical manifestations
9.10.4. Polycystic ovary syndrome (PCOS): characteristics and consequences

Module 10. Pharmacology of Oncohematologic Emergencies

10.1. Venous thromboembolism in oncohematological patients

10.1.1. Epidemiology and risk factors of VTE in oncohematologic patients
10.1.2. Diagnosis and classification of venous thromboembolism in patients with hematologic cancers
10.1.3. Pharmacology of anticoagulants used in the treatment and prevention of VTE in oncohematological patients
10.1.4. Use of thrombolytics in severe cases of VTE in oncohematologic patients

10.2. Tumor Lysis Syndrome

10.2.1. Classification and diagnosis of Tumor Lysis Syndrome
10.2.2. Use of allopurinol and rasburicase in the prevention and management of hyperuricemia in SLT
10.2.3. Treatment of electrolyte disturbances in the Tumor Lysis Syndrome
10.2.4. Pharmacologic management of hyperkalemia in patients with SLT

10.3. Tumor hypercalcemia

10.3.1. Mechanisms of action of tumors to provoke hypercalcemia
10.3.2. Types of tumors associated with Hypercalcemia
10.3.3. Diagnosis and classification of tumor hypercalcemia
10.3.4. Risk assessment and prognostic factors in patients with tumor hypercalcemia

10.4. Febrile Neutropenia

10.4.1. Mechanisms of action of tumors to provoke hypercalcemia
10.4.2. Types of tumors associated with Hypercalcemia
10.4.3. Diagnosis and classification of tumor hypercalcemia
10.4.4. Risk assessment and prognostic factors in patients with tumor hypercalcemia

10.5. Sickle cell disease

10.5.1. Genetics and inheritance of sickle cell disease
10.5.2. Diagnosis and Classification of sickle cell disease
10.5.3. Pharmacology of drugs used in the treatment and management of SCD
10.5.4. Use of hydroxyurea in the treatment and prevention of vasoocclusive crises

10.6. Mechanisms of development and progression of oncohematological diseases

10.6.1. Genetics and molecular biology of normal and cancerous hematopoietic cells
10.6.2. Mechanisms of malignant transformation of hematopoietic cells
10.6.3. Role of genetic mutations in hematologic oncogenesis
10.6.4. Tumor microenvironment and its influence on the progression of oncohematological diseases

10.7. Pharmacology of drugs used in Oncohematological Emergencies

10.7.1. Pharmacology of drugs used in stabilization and life support in oncohematological patients
10.7.2. Pharmacological management of acute hematological complications, such as severe anemia and thrombocytopenia
10.7.3. Pharmacotherapy in cases of febrile neutropenia in patients with blood cancers
10.7.4. Use of drugs for the control of acute pain in oncohematological patients

10.8. Treatment of febrile neutropenia

10.8.1. Etiology and risk factors of febrile neutropenia in oncologic and hematologic patients
10.8.2. Diagnosis and classification of Febrile Neutropenia
10.8.3. Pharmacology of antibiotics used in the empirical treatment of febrile neutropenia
10.8.4. Use of colony-stimulating factors (G-CSF) in the management of febrile neutropenia

10.9. Treatment of tumor lysis syndrome

10.9.1. Risk factors and prediction of the risk of developing tumor lysis syndrome
10.9.2. Diagnosis and classification of Tumor Lysis Syndrome
10.9.3. Pharmacology of drugs used in the prophylaxis and treatment of Tumor Lysis Syndrome
10.9.4. Use of allopurinol and rasburicase in the prevention and management of hyperuricemia in SLT

10.10. Leukemia and Lymphoma Emergencies

10.10.1. Oncohematologic Emergencies
10.10.2. Acute Leukemia Emergencies
10.10.3. Pharmacology of induction and consolidation treatments in acute leukemias
10.10.4. Treatment of infectious complications in patients with leukemias and lymphomas

A 100% online program through which you will manage with rigor the precise pharmacology for sexually transmitted diseases as a hospital pharmacist”